Further confirming the association of CD163 with poor clinical outcomes, Guo et al. (2021) described the association of a distinct monocyte/macrophage cluster by single-cell RNAseq, highly expressing CD163, with reduced probability of survival in AML patients (Guo et al., 2021). The gene discussed is CD163; the disease is acute myeloid leukemia.